Success Metrics

Clinical Success Rate

25.0%

Based on 1 completed trials

Completion Rate

25%(1/4)

Active Trials

1(13%)

Results Posted

100%(1 trials)

Terminated

3(38%)

Phase Distribution

Ph phase_3

13%

Ph phase_2

25%

Ph phase_1

38%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

3(50.0%)

Phase 2Efficacy & side effects

2(33.3%)

Phase 3Large-scale testing

1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Terminated(4)

Other(2)

Detailed Status

Terminated3

unknown2

Completed1

Recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

25.0%

Most Advanced

Phase 3

Trials by Phase

Phase 13 (50.0%)

Phase 22 (33.3%)

Phase 31 (16.7%)

Trials by Status

unknown225%

completed113%

terminated338%

recruiting113%

withdrawn113%

Recent Activity

1 active trials

Showing 5 of 8

recruitingphase_3

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

NCT05354141

terminatedphase_1

Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS

NCT04657458

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT05354141Phase 3

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Recruiting

NCT05130983Phase 1

Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease

Terminated

NCT05176366Phase 1

Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis

Terminated

NCT05836883Phase 1

Study of ExoFlo for the Treatment of Perianal Fistulas

Terminated

NCT04657458

Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS

Unknown

NCT05215288

Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients

Unknown

NCT04493242Phase 2

Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS

Completed

NCT05125562Phase 2

Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 8